Imatinib and other Abl1 inhibitors reduce cell proliferation, eliminating the symptoms of CML and rendering the presence of Philadelphia chromosomes undetectable [8]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.